3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other solid neoplasm
1
Conditions
Lymphoma
17
Leukemia, Myeloid, Acute
16
Breast Neoplasms
15
Precursor Cell Lymphoblastic Leukemia-Lymphoma
14
Multiple Myeloma
12
Lymphoma, Large B-Cell, Diffuse
12
Lymphoma, Non-Hodgkin
11
Carcinoma, Non-Small-Cell Lung
11
Lymphoma, Mantle-Cell
10
Leukemia
10
Lymphoma, Follicular
9
Hodgkin Disease
9
Myelodysplastic Syndromes
8
Recurrence
7
Neuroblastoma
7
Neoplasm Metastasis
7
Leukemia, Lymphocytic, Chronic, B-Cell
7
Brain Neoplasms
7
Neoplasms, Plasma Cell
6
Lymphoma, B-Cell, Marginal Zone
6
Lung Neoplasms
6
Glioblastoma
6
Prostatic Neoplasms
5
Pancreatic Neoplasms
5
Lymphoma, T-Cell, Cutaneous
5
Lymphoma, T-Cell
5
Lymphoma, Large-Cell, Anaplastic
5
Lymphoma, B-Cell
5
Immunoblastic Lymphadenopathy
5
Burkitt Lymphoma
5
Interventions
Pemetrexed
22
Cisplatin
20
Nivolumab
8
Gemcitabine
7
Carboplatin
7
durvalumab
5
Ipilimumab
5
Bevacizumab
5
pembrolizumab
4
Radiotherapy, Intensity-Modulated
4
tremelimumab
3
niraparib
3
Oxaliplatin
3
Drug Therapy
3
Cyclophosphamide
3
Cerebral Decortication
3
Blood Specimen Collection
3
sargramostim
2
Thoracoscopy
2
Surveys and Questionnaires
2
Sorafenib
2
Radiosurgery
2
Magnesium Sulfate
2
Leucovorin
2
Imatinib Mesylate
2
Hyperthermic Intraperitoneal Chemotherapy
2
Doxorubicin
2
Dexamethasone
2
tislelizumab
1
spartalizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Mesothelioma
×
Vorinostat
×
Clear all
NCT01353482
2012-03-22
MESO-02
University College, London
Phase 1/2
Withdrawn